The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk

IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk

June 8, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Immunosuppressants and anti-TNF drugs do not appear to increase the risk of extracolonic cancers in patients with inflammatory bowel disease (IBD), researchers from Spain report.

You Might Also Like
  • Does Methotrexate Increase Skin Cancer Risk?
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease
  • Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer

IBD patients face an increased risk of colon cancer, and some studies have suggested there might be an increased risk of extracolonic cancer.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Maria Chaparro from Hospital de La Princessa, in Madrid, and colleagues used data from the Spanish Working Group in Crohn’s and Colitis (GETECCU) prospective ENEIDA registry to investigate the incidence, prevalence and distribution of extracolonic cancer in more than 11,000 IBD patients and their possible association with treatment with immunosuppressants and anti-TNF agents.

Nearly half of the patients had been exposed to immunosuppressants or anti-TNF drugs: 45.8% to thiopurines, 4.7% to methotrexate and 21.6% to anti-TNF drugs, the team reports in The American Journal of Gastroenterology, online May 23.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

During a median follow-up of 98 months (range: 5–608 months), the overall incidence of extracolonic cancer was 0.36% per patient-year. The most prevalent extracolonic cancers were breast cancer (16.8% of the total), prostate cancer (12.3%), lung cancer (9.3%) and nonmelanoma skin cancer (8.8%).

On multivariate analysis, the only two factors significantly associated with a higher risk of developing an extracolonic cancer were older age at diagnosis of IBD and having been a smoker.

Treatment with immunosuppressants or anti-TNF drugs was not associated with the risk of extracolonic cancer overall or, specifically, with the development of lymphoma, leukemia, non-melanoma skin cancer or melanoma.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Chaparro did not respond to a request for comments.


Reference

  1. Chaparro M, Ramas M, Benítez JM, et al. Extracolonic cancer in inflammatory bowel disease: Data from the GETECCU Eneida Registry. Am J Gastroenterol. 2017 May 23. doi: 10.1038/ajg.2017.96. [Epub ahead of print]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Anti-TNF, anti-TNF agent, Cancer, IBD, inflammatory bowel disease, nonmelanoma skin cancer (NMSC)

You Might Also Like:
  • Does Methotrexate Increase Skin Cancer Risk?
  • Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease
  • Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer
  • Skin Complications of Anti-TNF Therapy Common in IBD

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)